Literature DB >> 18096352

Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.

Jason W Bennett1, Clinton K Murray, Robert L Holmes, Jan E Patterson, James H Jorgensen.   

Abstract

An elderly patient with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia was treated sequentially with vancomycin plus rifampin then daptomycin plus gentamicin. The MRSA strain developed diminished susceptibility to vancomycin (MIC increase and tolerance), daptomycin, and gentamicin, and resistance to rifampin during therapy.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18096352     DOI： 10.1016/j.diagmicrobio.2007.11.002

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  8 in total

1.  General principles of antimicrobial therapy.

Authors:  Surbhi Leekha; Christine L Terrell; Randall S Edson
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

2.  Daptomycin resistance and treatment failure following vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE).

Authors:  B A Cunha; F M Pherez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-01-28       Impact factor: 3.267

3.  Bioactive pyridine-N-oxide disulfides from Allium stipitatum.

Authors:  Gemma O'Donnell; Rosemarie Poeschl; Oren Zimhony; Mekala Gunaratnam; Joao B C Moreira; Stephen Neidle; Dimitrios Evangelopoulos; Sanjib Bhakta; John P Malkinson; Helena I Boshoff; Anne Lenaerts; Simon Gibbons
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 5.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

6.  Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.

Authors:  Kristina Nadrah; Franc Strle
Journal:  Chemother Res Pract       Date:  2011-04-18

7.  Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.

Authors:  Jennifer L Ross; Shannon Rankin; Patricia Marshik; Renée-Claude Mercier; Meghan Brett; Carla J Walraven
Journal:  Antibiotics (Basel)       Date:  2015-07-24

8.  Control of Methicillin-Resistant Staphylococcus aureus Pneumonia Utilizing TLR2 Agonist Pam3CSK4.

Authors:  Yi-Guo Chen; Yong Zhang; Lin-Qiang Deng; Hui Chen; Yu-Juan Zhang; Nan-Jin Zhou; Keng Yuan; Li-Zhi Yu; Zhang-Hua Xiong; Xiao-Mei Gui; Yan-Rong Yu; Xiao-Mu Wu; Wei-Ping Min
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.